Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone

被引：23

作者：

Ciniselli, Chiara Maura ^{[1
]}

De Bortoli, Maida ^{[2
]}

Taverna, Elena ^{[2
]}

Varinelli, Luca ^{[2
]}

Pizzamiglio, Sara ^{[1
]}

Veneroni, Silvia ^{[3
]}

Bonini, Chiara ^{[4
]}

Orlandi, Rosaria ^{[5
]}

Verderio, Paolo ^{[1
]}

Bongarzone, Italia ^{[2
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Unit Med Stat Biometry & Bioinformat, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Lab Prote, Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Biomarkers Unit, Milan, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Lab Med, Milan, Italy

[5] Fdn IRCCS Ist Nazl Tumori, Mol Targeting Unit, Milan, Italy

来源：

EXPERT REVIEW OF PROTEOMICS | 2015年 / 12卷 / 06期

关键词：

benign breast disease; BMP6; breast cancer; early diagnosis; erytroferrone; erytropoiesis; erytropoietin; hepcidin; IL-6; inflammation; iron metabolism; BONE MORPHOGENETIC PROTEINS; SERUM HEPCIDIN; ANEMIA; IRON; INFLAMMATION; PREVALENCE; CARCINOMA; CORRELATE; SURVIVAL; LEVEL;

D O I：

10.1586/14789450.2015.1099436

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Objective: Hepcidin-25 production is stimulated by systemic inflammation, and it interferes with iron utilization, leading to anemia. This study aimed to investigate the relationships between the plasma levels of hepcidin, interleukin-6 (IL-6), erythropoietin (EPO) and erythroferrone (ERFE) in patients with benign breast disease or cancer. Methods: Plasma samples from a cohort of 131 patients (47 with benign breast disease and 84 with breast cancer) were subjected to the evaluation of hepcidin, IL-6, EPO and ERFE using SELDI-TOF-MS or immunoassays. Results: An elevated hepcidin was observed in malignant breast tumors compared to benign ones. No correlation was observed between hepcidin and IL-6, EPO or ERFE. Conclusion: Since the study included a cohort of patients (87%) with breast cancers smaller than 2 cm, these results may support our previous evidence about the potential role of hepcidin in breast cancer disease.

引用

页码：695 / 701

页数：8

共 34 条

[1] Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?
Alarmo, Emma-Leena
Kallioniemi, Anne
[J]. ENDOCRINE-RELATED CANCER, 2010, 17 (02) : R123 - R139
[2] Bravais-Pearson and Spearman correlation coefficients: meaning, test of hypothesis and confidence interval
Artusi, R
Verderio, P
Marubini, E
[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (02) : 148 - 151
[3] Cancer-related anemia and recombinant human erythropoietin - an updated overview
Bohlius, J
Weingart, O
Trelle, S
Engert, A
[J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (03): : 152 - 164
[4] Camaschella C, 2008, COMMENT HAEMATOLOGIC, V93, P1473
[5] Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.3.CO
[6] 2-G
[7] Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD
Casanovas, Guillem
Mleczko-Sanecka, Katarzyna
Altamura, Sandro
Hentze, Matthias W.
Muckenthaler, Martina U.
[J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2009, 87 (05): : 471 - 480
[8] D'Auria L, 1997, EUR CYTOKINE NETW, V8, P383
[9] Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification
Durigovaa, Anna
Lamy, Pierre-Jean
Thezenas, Simon
Pouderoux, Stephane
Montels, Frederic
Romieu, Gilles
Gutowski, Marian
Jacot, William
[J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (09) : 1833 - 1841
[10] Enko D, 2013, BRIT J HAEMATOL, V161, P639

← 1 2 3 4 →